Sanofi (SNYNF) Research & Development (2009 - 2026)
Sanofi's (SNYNF) quarterly Research & Development came in at -$2.0 billion in Q1 2026, down 7.54% year-on-year from -$2.2 billion in Q1 2025, and up 77.59% quarter-over-quarter from -$9.1 billion in Q4 2025.
Sanofi (SNYNF) Research & Development (2009 - 2026) Analysis & Trends
Sanofi has disclosed Research & Development across 18 years of filings, most recently posting -$2.0 billion for Q1 2026.
- Research & Development for Q1 2026 came in at -$2.0 billion, down 7.54% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.8 billion (down 46.03% YoY), and the FY2025 annual result was $9.1 billion, up 15.53% from the prior year.
- Research & Development came in at -$2.0 billion for Q1 2026 at Sanofi, up from -$9.1 billion in the prior quarter.
- In the past five years, Research & Development ranged from a high of -$1.7 billion in Q1 2022 to a low of -$9.1 billion in Q4 2025.
- The 5-year median for Research & Development is -$1.9 billion (2025), against an average of -$3.5 billion.
- Across the five-year window, Research & Development declined 0.33% in 2023 and tumbled 227.92% in 2025, its largest moves.
- Sanofi's Research & Development stood at -$6.8 billion in 2022, then fell by 2.33% to -$7.0 billion in 2023, then retreated by 12.86% to -$7.9 billion in 2024, then slipped by 15.53% to -$9.1 billion in 2025, then soared by 77.59% to -$2.0 billion in 2026.
- The last three Research & Development figures came in at -$2.0 billion (Q1 2026), -$9.1 billion (Q4 2025), and -$6.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -2.28 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Sanofi | - | - | 9.49 Bn | -2.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.05 Bn |
| Dec 31, 2025 | -9.13 Bn |
| Sep 30, 2025 | -6.49 Bn |
| Jun 30, 2025 | -2.16 Bn |
| Mar 31, 2025 | -1.90 Bn |
| Dec 31, 2024 | -7.90 Bn |
| Sep 30, 2024 | -1.98 Bn |
| Jun 30, 2024 | -1.79 Bn |
| Mar 31, 2024 | -1.81 Bn |
| Dec 31, 2023 | -7.00 Bn |
| Sep 30, 2023 | -1.81 Bn |
| Jun 30, 2023 | -1.77 Bn |
| Mar 31, 2023 | -1.68 Bn |
| Dec 31, 2022 | -6.84 Bn |
| Sep 30, 2022 | -1.75 Bn |
| Jun 30, 2022 | -1.77 Bn |
| Mar 31, 2022 | -1.67 Bn |
| Dec 31, 2021 | -6.51 Bn |
| Sep 30, 2021 | -1.70 Bn |
| Jun 30, 2021 | -1.68 Bn |